India on the verge of becoming clinical trials hub, says Parexel executive
The US-based company plans to boost its headcount in India by more than 2,000 over the next three to five years, from about 6,000 currently, said Sanjay Vyas, who heads Parexel's India operations.
Vyas said India is well-placed to attract clinical trials disrupted by geopolitical conflicts such as the Russia-Ukraine war, as well as efforts by global drugmakers to reduce reliance on China.
Ukraine, along with Russia, had become important countries for studying new drugs before Russia's attack in 2022. In subsequent years, however, large companies and researchers have reported disruptions to trials there.
Vyas said Parexel plans to hire for roles that could help build innovation hubs.
"Because the cost of failure in India is much less than in other parts of the world," he said on the sidelines of the ongoing BioAsia conference in the southern state of Telangana.
Durham, North Carolina-headquartered Parexel, among the world's top clinical research organisations, operates between 100 and 150 trial sites in India, located across states including Maharashtra, Karnataka, Telangana and Tamil Nadu.
India's clinical trials data market is estimated to touch $1.51 billion in 2025, according to US-based GrandView Research.
While India's reputation as a trusted region for conducting trials is improving, several challenges, such as a lack of standardised regulations for some early-stage studies, remain before it can become a top choice for drugmakers.
"If you don't do phase 1 trials, the same patient will have to wait for a phase 3 (late-stage) trial to happen for the drug to come into the market. So you have the time lost, which you could have gotten earlier on if the molecule was already introduced in advance," Vyas said.
He also highlighted a lack of awareness about experimental treatments among patients and doctors, as well as establishing trial sites in remote areas, as other challenges in India.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
4 hours ago
- Gulf Today
New blood test detects early ovarian cancer
An experimental blood test detected early-stage ovarian cancer in patients with vague symptoms that would likely be misdiagnosed using currently available methods, researchers said in a new report. There are no reliable blood tests for these patients, and existing invasive tests often miss early-stage ovarian tumours, the researchers wrote in Cancer Research Communications. Using machine learning tools, the researchers identified multiple biomarkers - from across a wide range of molecules and processes in the body - that could be combined into a single test that detects all sub-types of the disease, at all stages. Tested at a large medical centre on blood samples from nearly 400 women with possible symptoms of ovarian cancer, the test was 92 percent accurate at identifying those with any stage of ovarian cancer and 88 percent accurate at identifying those with Stage I or Stage II disease, according to the report. Oriana Papin-Zoghbi, chief executive officer of the company developing the new test -Denver, Colorado-based AOA Dx - said the findings show its potential to aid 'in making faster, more informed decisions for women who need urgent clarity during a challenging diagnostic process.' Ovarian cancer is the fifth leading cause of cancer-related deaths among women, largely due to delays in diagnosis until after the disease has spread in the body, at which point it's harder to treat. More than 90 percent of patients with early-stage ovarian cancer experience symptoms that can be mistaken for benign conditions, such as bloating, abdominal pain, and digestive issues. WAM
Middle East Eye
2 days ago
- Middle East Eye
Food and medicine prevented from entering Gaza over accusations of 'dual military use': Report
Frustrated humanitarian aid drivers and United Nations officials criticised the obstacles they are facing transporting food and medicine into Gaza after they were turned back at the Egyptian border by Israel on Sunday, according to a report by Reuters. The news agency interviewed seven aid officials and three truck drivers on Monday, who said they faced obstacles such as "rejection of shipments for minor packing and paperwork issues", "heavy scrutiny over possible dual military use for a range of goods" and "short working hours at the Israeli border crossing". A World Health Organisation (WHO) employee working at the Rafah border told Reuters their cargo was blocked for carrying "illegal medicines". Reuters verified that they saw vehicles with the WHO's blue logos, and labels describing contents like topical medications and suction devices to clean wounds. Reuters said it asked the Israeli military authority in charge of coordinating aid into Gaza why the vehicles were not let into Gaza and did not receive a response.
Gulf Today
2 days ago
- Gulf Today
To stay on weight-loss drugs, US patients cut doses
Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more US insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are weekly injections with US insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. "A significant number of my patients now pay cash," said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. "People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two." More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss, reported Reuters. "My new company does not cover GLP-1s, so now I am in a kind of purgatory," Kibasova said. "I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight." The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription "cold turkey," so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. Peters said she uses "every technique in the book" to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. US pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials.
